Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04443088 · ClinicalTrials.gov registry record · Phase 1
An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
A Phase 1 study of Cancer and Solid Tumor, Adult, sponsored by Shenzhen Ionova Life Sciences Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 78
- Enrollment target
- 3
- Study locations
NCT04443088 is a Phase 1 study of Cancer and Solid Tumor, Adult that is actively recruiting participants, run by Shenzhen Ionova Life Sciences Co.. The registered enrollment target is 78 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT04443088, a Phase 1 study of Cancer and Solid Tumor, Adult, is actively recruiting participants, sponsored by Shenzhen Ionova Life Sciences Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 78 participants
- Enrollment target
- 3
- Study locations
Study Summary
Phase 1, open-label dose-escalation study to determine the MTD of INV-1120 and RP2D, and to assess the DLT of INV-1120 as a single agent or in the combination with pembrolizumab. The safety, tolerability, and PK of INV-1120 as a single agent or in the combination with pembrolizumab will be assessed in adult patients with advanced solid tumors.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Pembrolizumab
- DRUG INV-1120
Study Locations (3)
Texas
- START - San Antonio
- UT Health - San Antonio
Indiana
- Horizon Oncology Research, LLC, - Lafayette
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2020-06-26 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04443088
The ClinicalTrials.gov registry entry for NCT04443088 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Shenzhen Ionova Life Sciences Co., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04443088 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Texas, Indiana.
Frequently Asked Questions
What is clinical trial NCT04443088 about?
NCT04443088 is a clinical study titled "An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors". Phase 1, open-label dose-escalation study to determine the MTD of INV-1120 and RP2D, and to assess the DLT of INV-1120 as a single agent or in the combination with pembrolizumab. The safety, tolerability, and PK of INV-1120 as a single agent or in the combination with pembrolizumab will be assessed ...
What is the current status of trial NCT04443088?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2020-06-26. Estimated completion is 2026-12-31.
What conditions does trial NCT04443088 study?
This clinical trial studies the following conditions: Cancer, Solid Tumor, Adult, Tumor, Solid, Cancer Metastatic, Solid Carcinoma.
What interventions are being tested in trial NCT04443088?
The interventions under investigation include: Pembrolizumab (COMBINATION_PRODUCT), INV-1120 (DRUG).
Who is sponsoring clinical trial NCT04443088?
This trial is sponsored by Shenzhen Ionova Life Sciences Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04443088 being conducted?
This trial has 3 study locations across Indiana, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.